Is it time to screen the general population for type 1 diabetes?

US Endocrinology

Volumn 11, Issue 1, 2015, Pages 10-16

  Simmons, Kimber M ^a   Michels, Aaron W ^b  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

General population; Islet autoantibodies; Prediction; Risk; Screening; Type 1 diabetes

Indexed keywords

EID: 84928813865     PISSN: 17583918     EISSN: 17583926     Source Type: Journal    
DOI: 10.17925/use.2015.11.1.10     Document Type: Article

References (75)

1. Atkinson MA, Eisenbarth GS, Michels AW., Type 1 diabetes, Lancet, 2014;383:69-82.
2. Ziegler AG, Rewers M, Simell O, et al., Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children, JAMA, 2013;309:2473-9.
3. Eisenbarth GS., Type I diabetes mellitus: a chronic autoimmune disease, N Engl J Med, 1986;314:1360-8.
4. Hagopian WA, Sanjeevi CB, Kockum I, et al., Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children, J Clin Invest, 1995;95:1505-11.
5. Rewers M, Bugawan TL, Norris JM, et al., Newborn screening for HLA markers associated with IDDM: diabetes autoimmunity study in the young (DAISY), Diabetologia, 1996;39:807-12.
6. Nejentsev S, Sjoroos M, Soukka T, et al., Population-based genetic screening for the estimation of type 1 diabetes mellitus risk in Finland: selective genotyping of markers in the HLA-DQB1, HLA-DQA1 and HLA-DRB1 loci, Diabet Med, 1999;16:985-92.
7. Kimpimaki T, Kulmala P, Savola K, et al., Natural history of betacell autoimmunity in young children with increased genetic susceptibility to type 1 diabetes recruited from the general population, J Clin Endocrinol Metab, 2002;87:4572-9.
8. Barker JM, Barriga KJ, Yu L, et al., Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY), J Clin Endocrinol Metab, 2004;89:3896-902.
9. Bottazzo GF, Florin-Christensen A, Doniach D., Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies, Lancet, 1974;2:1279-83.
10. Yu L, Dong F, Miao D, et al., Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity, Diabetes Care, 2013;36:2266-70.
11. Miao D, Guyer KM, Dong F, et al., GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes, Diabetes, 2013;62:4174-8.
12. Miao D, Steck AK, Zhang L, et al., Electrochemiluminescence assays for insulin and glutamic acid decarboxylase autoantibodies improve prediction of type 1 diabetes risk, Diabetes Technol Ther, 2015;17:119-27.
13. Vardi P, Ziegler AG, Mathews JH, et al., Concentration of insulin autoantibodies at onset of type I diabetes: inverse log-linear correlation with age, Diabetes Care, 1988;11:736-9.
14. Bingley PJ, Bonifacio E, Mueller PW., Diabetes Antibody Standardization Program: first assay proficiency evaluation, Diabetes, 2003;52:1128-36.
15. Schlosser M, Mueller PW, Torn C, et al., Participating L, Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies, Diabetologia, 2010;53:2611-20.
16. Xu P, Beam CA, Cuthbertson D, et al., Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis, Diabetes Care, 2012;35:1975-80.
17. Sosenko JM, Palmer JP, Greenbaum CJ, et al., Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1, Diabetes Care, 2006;29:643-9.
18. Dabelea D, Rewers A, Stafford JM, et al., Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for diabetes in youth study, Pediatrics, 2014;133:e938-45.
19. Group DP., Incidence and trends of childhood type 1 diabetes worldwide 1990-1999, Diabet Med, 2006;23:857-66.
20. Harjutsalo V, Sjoberg L, Tuomilehto J., Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study, Lancet, 2008;371:1777-82.
21. Patterson CC, Dahlquist GG, Gyurus E, et al., Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study, Lancet, 2009;373:2027-33.
22. Lipman TH, Levitt Katz LE, Ratcliffe SJ, et al., Increasing incidence of type 1 diabetes in youth: twenty years of the Philadelphia Pediatric Diabetes Registry, Diabetes Care, 2013;36:1597-603.
23. Lawrence JM, Imperatore G, Dabelea D, et al., Trends in incidence of type 1 diabetes among non-Hispanic white youth in the United States, 2002-2009, Diabetes, 2014;63:3938-45.
24. Elding Larsson H, Vehik K, Gesualdo P, et al., Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease, Pediatr Diabetes, 2014;15:118-26.
25. Steck AK, Johnson K, Barriga KJ, et al., Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes:diabetes autoimmunity study in the young, Diabetes Care, 2011;34:1397-9.
26. Steck AK, Vehik K, Bonifacio E, et al., Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: the environmental determinants of diabetes in the young (TEDDY), Diabetes Care, 2015 [Epub ahead of print].
27. Geographic patterns of childhood insulin-dependent diabetes mellitus., Diabetes Epidemiology Research International Group, Diabetes, 1988;37:1113-9.
28. Imperatore G, Boyle JP, Thompson TJ, et al., Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth, Diabetes Care, 2012;35:2515-20.
29. Sosenko JM, Palmer JP, Rafkin-Mervis L, et al., Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1, Diabetes Care, 2009;32:1603-7.
30. Sosenko JM, Skyler JS, Beam CA, et al., Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants, Diabetes, 2013;62:4179-83.
31. Sosenko JM, Skyler JS, Herold KC, Palmer JP., Type 1 Diabetes T, Diabetes Prevention Trial-Type 1 Study G: the metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-Type 1, Diabetes, 2012;61:1331-7.
32. Veijola R, Reijonen H, Vahasalo P, et al., HLA-DQB1-defined genetic susceptibility, beta cell autoimmunity, and metabolic characteristics in familial and nonfamilial insulin-dependent diabetes mellitus, Childhood Diabetes in Finland (DiMe) Study Group, J Clin Invest, 1996;98:2489-95.
33. Dahlquist G, Blom L, Holmgren G, et al., The epidemiology of diabetes in Swedish children 0-14 years-a six-year prospective study, Diabetologia, 1985;28:802-8.
34. Aly TA, Ide A, Humphrey K, et al., Genetic prediction of autoimmunity: initial oligogenic prediction of anti-islet autoimmunity amongst DR3/DR4-DQ8 relatives of patients with type 1A diabetes, J Autoimmun, 2005;25 Suppl:40-5.
35. Gullstrand C, Wahlberg J, Ilonen J, et al., Progression to type 1 diabetes and autoantibody positivity in relation to HLA-risk genotypes in children participating in the ABIS study, Pediatr Diabetes, 2008;9(3 Pt 1):182-90.
36. Standards of medical care in diabetes-2015: summary of revisions, Diabetes Care, 2015;Suppl. 38:S4.
37. Maclaren NK, Horne, G, Spillar, RP, et al., Islet cell autoantibodies (ICA) in US school children, Diabetes, 1985;34(Suppl. 1):84A.
38. Atkinson MA, Maclaren NK, Riley WJ, et al., Are insulin autoantibodies markers for insulin-dependent diabetes mellitus?, Diabetes, 1986;35:894-8.
39. Bergua M, Sole J, Marion G, et al., Prevalence of islet cell antibodies, insulin antibodies and hyperglycaemia in 2291 schoolchildren, Diabetologia, 1987;30:724-6.
40. Bruining GJ, Molenaar JL, Grobbee DE, et al., Ten-year follow-up study of islet-cell antibodies and childhood diabetes mellitus, Lancet, 1989;1:1100-3.
41. Karjalainen JK., Islet cell antibodies as predictive markers for IDDM in children with high background incidence of disease, Diabetes, 1990;39:1144-50.
42. Boehm BO, Manfras B, Seissler J, et al., Epidemiology and immunogenetic background of islet cell antibody-positive nondiabetic schoolchildren, Ulm-Frankfurt population study, Diabetes, 1991;40:1435-9.
43. Aanstoot HJ, Sigurdsson E, Jaffe M, et al., Value of antibodies to GAD65 combined with islet cell cytoplasmic antibodies for predicting IDDM in a childhood population, Diabetologia, 1994;37:917-24.
44. Schatz D, Krischer J, Horne G, et al., Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives, J Clin Invest, 1994;93:2403-7.
45. Levy-Marchal C, Dubois F, Noel M, et al., Immunogenetic determinants and prediction of IDDM in French schoolchildren, Diabetes, 1995;44:1029-32.
46. Bingley PJ, Bonifacio E, Williams AJ, et al., Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers, Diabetes, 1997;46:1701-10.
47. Strebelow M, Schlosser M, Ziegler B, et al., Karlsburg Type I diabetes risk study of a general population: frequencies and interactions of the four major Type I diabetes-associated autoantibodies studied in 9419 schoolchildren, Diabetologia, 1999;42:661-70.
48. Kulmala P, Rahko J, Savola K, et al., Beta-cell autoimmunity, genetic susceptibility, and progression to type 1 diabetes in unaffected schoolchildren, Diabetes Care, 2001;24:171-3.
49. Samuelsson U, Sundkvist G, Borg H, et al., Islet autoantibodies in the prediction of diabetes in school children, Diabetes Res Clin Pract, 2001;51:51-7.
50. LaGasse JM, Brantley MS, Leech NJ, et al., Successful prospective prediction of type 1 diabetes in schoolchildren through multiple defined autoantibodies: an 8-year follow-up of the Washington State Diabetes Prediction Study, Diabetes Care, 2002;25:505-11.
51. Maclaren NK, Lan MS, Schatz D, et al., Multiple autoantibodies as predictors of type 1 diabetes in a general population, Diabetologia, 2003;46:873-4.
52. Schlosser M, Strebelow M, Rjasanowski I, et al., Prevalence of diabetes-associated autoantibodies in schoolchildren:the Karlsburg Type 1 Diabetes Risk Study, Ann N Y Acad Sci, 2004;1037:114-7.
53. Gianani R, Putnam A, Still T, et al., Initial results of screening of nondiabetic organ donors for expression of islet autoantibodies, J Clin Endocrinol Metab, 2006;91:1855-61.
54. Knip M, Korhonen S, Kulmala P, et al., Prediction of type 1 diabetes in the general population, Diabetes Care, 2010;33:1206-12.
55. Siljander HT, Veijola R, Reunanen A, et al., Prediction of type 1 diabetes among siblings of affected children and in the general population, Diabetologia, 2007;50:2272-5.
56. Skyler JS, Greenbaum CJ, Lachin JM, et al., Type 1 Diabetes TrialNet-an international collaborative clinical trials network, Ann N Y Acad Sci, 2008;1150:14-24.
57. Simmons K, Michels AW., Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease, rheumatic diseases clinics of North America, 2014;40:797-811.
58. Michels AW, von Herrath M., 2011 update: antigen-specific therapy in type 1 diabetes, Curr Opin Endocrinol Diabetes Obes, 2011;18:235-40.
59. Diabetes Prevention Trial-Type 1 Diabetes Study G: Effects of insulin in relatives of patients with type 1 diabetes mellitus, N Engl J Med, 2002;346:1685-91.
60. Vehik K, Cuthbertson D, Ruhlig H, et al., Long-term outcome of individuals treated with oral insulin: diabetes prevention trialtype 1 (DPT-1) oral insulin trial, Diabetes Care, 2011;34:1585-90.
61. Herold KC, Gitelman SE, Masharani U, et al., A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes, Diabetes, 2005;54:1763-9.
62. Haller MJ, Gitelman SE, Gottlieb PA, et al., Anti-thymocyte globulin/G-CSF treatment preserves beta cell function in patients with established type 1 diabetes, J Clin Invest, 2015;125:448-55.
63. Orban T, Bundy B, Becker DJ, et al., Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes:follow-up 1 year after cessation of treatment, Diabetes Care, 2014;37:1069-75.
64. Pescovitz MD, Greenbaum CJ, Bundy B, et al., B-lymphocyte depletion with rituximab and beta-cell function: two-year results, Diabetes Care, 2014;37:453-9.
65. Keymeulen B, Walter M, Mathieu C, et al., Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recentonset type 1 diabetic patients depends on their age and baseline residual beta cell mass, Diabetologia, 2010;53:614-23.
66. Wald NJ., Guidance on terminology, J Med Screen, 2001;8:56.
67. Wilson JM, Jungner YG., Principles and practice of mass screening for disease, Bol Oficina Sanit Panam, 1968;65:281-393.
68. Dall TM, Zhang Y, Chen YJ, et al., The economic burden of diabetes, Health Affair, 2010;29:297-303.
69. Dall TM, Yang W, Halder P, et al., The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes, Diabetes Care, 2014;37:3172-9.
70. Maldonado MR, Chong ER, Oehl MA, Balasubramanyam A., Economic impact of diabetic ketoacidosis in a multiethnic indigent population: analysis of costs based on the precipitating cause, Diabetes Care, 2003;26:1265-9.
71. Gregg EW, Li Y, Wang J, et al., Changes in diabetes-related complications in the United States, 1990-2010, N Engl J Med, 2014;370:1514-23.
72. Cameron FJ, Scratch SE, Nadebaum C, et al., Neurological consequences of diabetic ketoacidosis at initial presentation of type 1 diabetes in a prospective cohort study of children, Diabetes Care, 2014;37:1554-62.
73. Lin A, Northam EA, Werther GA, Cameron FJ., Risk factors for decline in IQ in youth with type 1 diabetes over the 12 years from diagnosis/illness onset, Diabetes Care, 2015;38:236-42.
74. Triolo TM, Chase HP, Barker JM, Group DPTS., Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset, Diabetes Care, 2009;32:769-73.
75. Ludvigsson J, Gustafsson-Stolt U, Liss PE, Svensson T, Group AS., Mothers of children in ABIS, a population-based screening for prediabetes, experience few ethical conflicts and have a positive attitude, Ann N Y Acad Sci, 2002;958:376-81.